Mobile Menu

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Mitochondrial Neuropathy
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us
  • Menu
  • Skip to primary navigation
  • Skip to main content

https://eyecro.com

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • DL-AAA Retinal Leakage
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Mitochondrial Neuropathy
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • A2E Quantification
    • Bioanalytical Detection
    • Biochemistry
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us

Preclinical Ophthalmic Contract Research

biotechnology

Roche CEO ‘sleeps better’ as risk to drugmaker’s growth recedes

June 28, 2016 //  by stanselb

LONDON (Reuters) - Roche (ROG.S) is increasingly confident it will continue to lift sales and profit even as cut-rate copies of the Swiss drugmaker's older cancer medicines start to grab business next year, its chief executive said on Wednesday. In February the company won U.S. Food and Drug Administration (FDA) breakthrough status for new multiple sclerosis drug Ocrevus. That was followed in …

Category: NewsTag: biotechnology, research

RetroSense Therapeutics to Present at the 8th Ocular Diseases Drug Discovery Conference

March 14, 2016 //  by stanselb

RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD).  RetroSense is developing optogenetic approaches to partial vision restoration in retinitis pigmentosa and potentially dry …

Category: NewsTag: Age-related macular degeneration, biotechnology, blindness, dry amd, gene therapies, retinitis pigmentosa, RP, vision

Spark Surges in IPO as Prices Fuel Gene Therapy

February 4, 2015 //  by stanselb

Spark Therapeutics Inc. hit a $1.2 billion valuation on the biotechnology firm’s first day on the market, reflecting growing investor enthusiasm for the once-beleaguered field of gene therapy, a field that has produced the first $1 million drug.  The treatments focus on diseases where a single mutation in the genetic code is known to be the cause. Fix or replace the genetic code, and, …

Category: NewsTag: Age-related macular degeneration, Avalanche, Biogen Idec Inc., biotechnology, blind, eye disorders, gene therapy, Pfizer Inc., Spark Therapeutics Inc.

© 2023 · EyeCRO · All Rights Reserved.